2 citations
,
May 2023 in “The Journal of Immunology” This animal study observed that treatment with the S1PR modulator NXC736 significantly reduced lesion area and CD8+ T cell infiltration in mice with alopecia areata, suggesting its potential as a promising therapy for the condition.
November 2025 in “The Journal of Immunology” This study found that administering an S1PR 1&4 modulator reduced alopecia areata lesion size and decreased CD8+ T cell infiltration in mice, suggesting potential as a treatment for this condition.
November 2025 in “Frontiers in Immunology” This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.
1 citations
,
January 2018 This study found that sphingosine 1-phosphate and its receptor S1PR3 are essential in regulating the acute mechanical pain response, highlighting their role in mechanonociception without affecting responses to innocuous touch or thermal stimuli.